Janet Shipley

Has grant

Group Leader, Sarcoma Molecular Pathology

Institute of Cancer Research
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Unravelling Transition processes between Epithelial and Mesenchymal cells in Desmoplastic Small Round Cell Tumours to Improve Treatment options

Open Date: 2026-01-01

Close Date: 2027-12-01

Grant: Open

Development Of Natural Killer Cell Immunotherapy for Paediatric Rhabdomyosarcoma

Open Date: 2026-01-01

Close Date: 2029-01-01

Grant: Open

Epigenetic therapies to enhance the immune response of paediatric rhabdomyosarcomas

Open Date: 2024-01-01

Close Date: 2027-01-01

Grant: Open

Facilitating Current and Future Molecular Biological Studies of Rhabdomyosarcoma (RMS) through Improved Management of Sample Collection and Data

Open Date: 2024-01-01

Close Date: 2027-01-01

Grant: Open

Defining plasticity in RhabdoMyoSarcoma (RMS) cells: A new approach to derive new treatments that prevent or treat relapse

Open Date: 2023-01-01

Close Date: 2027-01-01

Articles (22)

Year:

2026

Year:

2026

Desmoplastic small round cell tumor (DSRCT) is an aggressive sarcoma subtype that is driven by the EWS–WT1 chimeric transcription factor. The prognosis for DSRCT is poor, and major advances in treating DSRCT have not occurred for over two decades. To identify effective therapeutic approaches to target DSRCT, we conducted a high-throughput drug sensitivity screen in a DSRCT cell line assessing chemosensitivity profiles for 79 small-molecule inhibitors. DSRCT cells were sensitive to PARP inhibitors (PARPi) and ataxia–telangiectasia and Rad3–related inhibitors (ATRi), as monotherapies and in combination. These effects were recapitulated using multiple clinical PARPi and ATRi in three biologically distinct, clinically relevant models of DSRCT, including cell lines, a patient-derived xenograft–derived organoid model, and a cell line–derived xenograft mouse model. Mechanistically, exposure to a combination of PARPi and ATRi caused increased DNA damage, G2–M checkpoint activation, micronuclei accumulation, replication stress, and R-loop formation. EWS–WT1 silencing abrogated these phenotypes and was epistatic with exogenous expression of the R-loop resolution enzyme RNase H1 in reversing sensitivity to PARPi and ATRi monotherapies. The combination of PARPi and ATRi also induced EWS–WT1–dependent cell-autonomous activation of the cyclic GMP–AMP synthase–stimulator of IFN genes innate immune pathway and cell-surface expression of PD-L1. Taken together, these findings point toward a role for EWS–WT1 in generating R-loop–dependent replication stress that leads to a targetable vulnerability, providing a rationale for the clinical assessment of PARPi and ATRi in DSRCT. Significance: EWS–WT1, the unique oncogenic driver of desmoplastic small round cell tumors, confers sensitivity to PARP and ATR inhibitors, supporting the potential of these drugs in treating patients with this aggressive sarcoma subtype.

Year:

2025

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and young people. Despite the advances in multimodality treatment over recent decades through successive prospective clinical trials, improved rates of survival for patients are mainly limited to those with localised RMS without adverse biologic features. Current clinicopathologic prognostic factors include PAX3(7)::FOXO1 fusion status, the site of primary disease, the pre-chemotherapy extent of disease (including microscopic vs. macroscopic residual disease, locoregional nodal involvement and metastatic status), tumour size and patient age. These factors are used to stratify patients into prognostic risk groups that guide treatment intensity and duration. Risk stratification algorithms are evolving, supported by advances in molecular biology and cancer genomics. In this review we focus on the poorest prognostic groups of paediatric-type RMS (i.e., Very High Risk or relapsed/progressive disease). These include patients whose tumours harbour poor biological characteristics such as PAX3(7)::FOXO1 fusion-positive tumours with locoregional nodal involvement and tumours harbouring other poor-risk genetic variants (particularly MYOD1 and TP53 variants); adolescent and young adult patients; newly diagnosed patients with metastatic RMS; and patients with relapsed and refractory disease. Here we aim to describe the clinical characteristics of these patients, outline current standard multimodality treatments in the context of sequential international clinical trials across the major cooperative groups and summarise emerging novel diagnostic and therapeutic approaches.

Year:

2025

Year:

2025

Year:

2025

Background Patients with PAX3/7‐FOXO1 fusion‐negative rhabdomyosarcomas (fnRMS) harbouring the rare L122R MYOD1 mutation have significantly poorer prognosis than other fnRMS. We undertook a detailed clinicopathological evaluation of a cohort of patients with MYOD1 mutat ed fnRMS in order to improve risk stratification and treatment options. Procedure Histological, mutational and clinical data from a cohort of patients with MYOD1 mutant RMS treated in Europe were analysed. Results Thirty‐two cases with mutant MYOD1 RMS were identified from patients enrolled in sequential European rhabdomyosarcoma clinical trials from 1992 to 2022 ( n = 22) and non‐trial cohorts ( n = 10). Thirty cases had the recurrent L122R missense mutation, one case harboured a K124E mutation and one case had a truncating mutation (S63X). Increased MyoD1 and reduced MYF4 immunostaining were consistent features of MYOD1 L122R ‐mutated RMS. Applying the risk stratification of the European paediatric Soft tissue sarcoma Study Group (E p SSG) RMS2005 trial, among 20 localised RMS cases that could be assigned a risk category, one was Very High Risk, 13 were High Risk and six were Standard Risk. Eight patients had distant metastases at diagnosis. Of the 25 patients with adequate clinical follow‐up data, 15/25 (60%) patients had an event at a median time of 9 months (12/15 included failure of local control) and 13/25 (52%) died of disease. Conclusion This MYOD1 mutant cohort demonstrates increased MYOD and reduced MYF4 immunostaining, high risk of local failure and poor survival in agreement with other studies. Increased treatment intensity and improved local control should be considered for these patients.

Year:

2025

A5/158-vc-MMAE decreases the number and size of spontaneous metastases. Continuation of Fig. 5 . A, Ex vivo IVIS imaging and quantification of lungs at endpoint (mean values ± SEM, two-sided Mann–Whitney U test). B, Representative FFPE lung sections stained for lamin A/C at 3 levels 150 μm apart. Scale bar, 100 μm. C, Quantification of the number of metastatic lung lesions, average area of lung lesions, and % metastatic area of lung lesions (mean of three sections per mouse). Data shown are mean values ± SEM; number of lung lesions, two-sided Mann–Whitney U test; average area of lung lesions and metastatic tumor area, two-sided unpaired t test. D, Proportion of mice with liver metastases. E, Proportion of mice with lymph node metastases.

Year:

2025

Endo180 protein expression in sarcoma cell lines compared to epithelial cancer cells by immunofluorescence. Additionally, this figure shows the isotype control antibody conjugated to AlexaFluor 488 is not internalized into Endo180 expressing sarcoma cell lines and is not trafficked to the lysosome.

Year:

2025

Endo180 expressing cell lines are sensitive to A5/158-vc-MMAE. A, Schematic representation of an antibody conjugated to an MMAE payload (green) via a cleavable valine–citrulline linker (pink). B, Endo180-positive and Endo180-negative cell lines were treated with A5/158-vc-MMAE or isotype-vc-MMAE for 72 hours. Shown are representative graphs (independent experiments n = 3) of cell viability readouts determined by CellTiter-Glo. Data are normalized to untreated cells ( n = 3 wells per condition, mean values ± SEM).

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (37)

Christopher Lord

Professor of Cancer Genomics

Institute of Cancer Research

UNITED KINGDOM
View details

Clare Isacke

Professor of Molecular Cell Biology

Institute of Cancer Research

UNITED KINGDOM
View details

Etienne Schwob

Senior Group Leader (DR2)

CNRS Délégation Languedoc-Roussillon

FRANCE
View details

Noé Herbel

Institut Gustave Roussy

FRANCE
View details

Neil Sebire

University College London

UNITED KINGDOM
View details

Michael Hubank

Professor of Translational Genomics

University College London

UNITED KINGDOM
View details

Juliet Gray

Professor of Paediatric Oncology

University of Southampton

UNITED KINGDOM
View details

Chris Jones

Professor of Childhood Brain Tumour Biology

Institute of Cancer Research

UNITED KINGDOM
View details

Sophie Postel-Vinay

Institut Gustave Roussy

FRANCE
View details

Steven C. Clifford

Prof of Molecular Paediatric Oncology

Newcastle University

UNITED KINGDOM
View details

Zoe Walters

Professor

University of Southampton

UNITED KINGDOM
View details

Susanne Andrea Gatz

University of Birmingham

UNITED KINGDOM
View details

William Anderson

University College London

UNITED KINGDOM
View details

Mark Hatley

Associate Member

St. Jude Children's Research Hospital

UNITED STATES
View details

Guy Makin

Senior Lecturer in Paediatric Oncology

The University of Manchester

UNITED KINGDOM
View details

Sibylle Mittnacht

University College London

UNITED KINGDOM
View details

Trevor A Graham

Director

Institute of Cancer Research

UNITED KINGDOM
View details

Sapna Oberoi

Associate Professor

University of Manitoba

CANADA
View details

Reuben Pengelly

Principal Teaching Fellow

University of Southampton

UNITED KINGDOM
View details

Deborah A. Tweddle

-

UNITED KINGDOM
View details

Ridwan Shaikh

Institute of Cancer Research

UNITED KINGDOM
View details

Bissan Al-Lazikani

Professor, Director of Therapeutics Data Science

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Roman M. Chabanon

Post-doctoral research fellow

Institut Gustave Roussy

FRANCE
View details

Nathaniel Anderson

Wellcome Sanger Institute

UNITED KINGDOM
View details

Sally George

Institute of Cancer Research

UNITED KINGDOM
View details

Guillaume PINNA

Head of a High Content Screening facility

Commissariat à l'Énergie Atomique et aux Énergies Alternatives

FRANCE
View details

Richard Grundy

Professor of Paediatric Neuro-Oncology and Cancer Biology

University of Nottingham

UNITED KINGDOM
View details

Louis Chesler

professor

Institute of Cancer Research

UNITED KINGDOM
View details

Alice Piapi

University College London

UNITED KINGDOM
View details

Amos Burke

Professor of Paediatric Oncology and Director

University of Birmingham

UNITED KINGDOM
View details

Gianni Bisogno

Docenti di ruolo di Ia fascia

University of Padova

ITALY
View details

Isidro Cortes Ciriano

Research Group Leader

European Bioinformatics Institute

UNITED KINGDOM
View details

Andrea Sottoriva

Head

Human Technopole

ITALY
View details

Darren Hargrave

University College London

UNITED KINGDOM
View details

Carolin Sauer

Group Leader

Vall d'Hebron Institute of Oncology

SPAIN
View details

Pamela Kearns

University of Birmingham

UNITED KINGDOM
View details

Meritxell B. Cutrona

Head of Platform | Patient-derived organoids for Precision Medicine

Institut Gustave Roussy

FRANCE
View details